Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Inclusion Criteria: * Histologically confirmed germ cell tumor (GCT) * Seminoma or non-seminoma * Progressive disease after prior cisplatin-based therapy AND meets 1 of the following criteria: * Not considered to be a candidate for potentially curative therapy * Previously treated with high-dose chemotherapy regimens * Does not wish to undergo potentially curative high-dose therapy * Measurable or evaluable disease, as defined by 1 of the following criteria: * Unidimensionally measurable metastatic disease, defined as ≥ 1 malignant tumor mass that can be accurately measured in ≥ 1 dimension as ≥ 20 mm by conventional CT scan or MRI or as ≥ 10 mm by spiral CT scan * Bone lesions, ascites, peritoneal carcinomatosis, miliary lesions, pleural or pericardial effusions, lymphangitis of the skin or lung, cystic lesions, or irradiated lesions are not considered measurable disease * Patients with measurable disease only (i.e., normal tumor markers) must have ≥ 1 site of disease that has not been previously irradiated * Elevation of alpha-fetoprotein \> 15 ng/mL and/or elevation of beta-human chorionic gonadotropin \> 2.2 mIU/L * If tumor markers are not elevated, ≥ 1 site of measurable disease must be present * No known untreated CNS metastasis or primary CNS tumor * Patients who have undergone local treatment for brain metastases and whose brain metastases are demonstrated to be stable by repeat imaging studies performed ≥ 4 weeks after treatment are …